Tuesday 18 September 2018

Induction of Mitochondrial Dysfunction and Oxidative Damage by Antibiotic Drug Doxycycline Enhances the Responsiveness of Glioblastoma to Chemotherapy.

https://www.ncbi.nlm.nih.gov/pubmed/28842551

Any opinions on this study? Dosage in humans?

2 comments:

  1. Unfortunately this used a subcutaneous, flank-injected tumor model, so it bypassed the critical issue of the blood-brain barrier. We do have several examples of intracranial glioma mouse models showing therapeutic effects for minocycline, which is in the same drug class as doxycycline. Based on these studies, minocycline is included in CUSP9v3, which is in clinical trial in Germany. See here for dosing:
    https://clinicaltrials.gov/ct2/show/NCT02770378

    ReplyDelete
    Replies
    1. See also

      https://clinicaltrials.gov/ct2/show/NCT01580969

      and

      https://clinicaltrials.gov/ct2/show/NCT02272270

      https://academic.oup.com/neuro-oncology/article-abstract/19/suppl_6/vi19/4590364?redirectedFrom=fulltext

      Unfortunately the phase 1 trial was not overly successful for an unselected GBM population. "A signal of efficacy was not seen. Further investigation of minocycline in unselected high grade glioma is not warranted, though biomarkers of NF-kappaB activation and mesenchymal phenotype are being investigated."

      Delete